115 related articles for article (PubMed ID: 7834120)
21. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
Grünwald V; Desar IM; Haanen J; Fiedler W; Mouritzen U; Olsen MW; van Herpen CM
Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
[TBL] [Abstract][Full Text] [Related]
22. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
23. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma.
Dosquet C; Schaetz A; Faucher C; Lepage E; Wautier JL; Richard F; Cabane J
Eur J Cancer; 1994; 30A(2):162-7. PubMed ID: 8155390
[TBL] [Abstract][Full Text] [Related]
24. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2.
Bukowski RM
Cancer; 1997 Oct; 80(7):1198-220. PubMed ID: 9317170
[TBL] [Abstract][Full Text] [Related]
25. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
[TBL] [Abstract][Full Text] [Related]
26. Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus.
Doganay S; Evereklioglu C; Er H; Türköz Y; Sevinç A; Mehmet N; Savli H
Eye (Lond); 2002 Mar; 16(2):163-70. PubMed ID: 11988817
[TBL] [Abstract][Full Text] [Related]
27. Serum levels of TNF-alpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease.
Evereklioglu C; Er H; Türköz Y; Cekmen M
Mediators Inflamm; 2002 Apr; 11(2):87-93. PubMed ID: 12061429
[TBL] [Abstract][Full Text] [Related]
28. In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses.
Deehan DJ; Heys SD; Simpson WG; Broom J; Franks C; Eremin O
Br J Cancer; 1994 Jun; 69(6):1130-5. PubMed ID: 8198981
[TBL] [Abstract][Full Text] [Related]
29. Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors.
Stahel RA; Sculier JP; Jost LM; Delforge A; Bron D; Gmür J; Oelz O; Sauter C; Stryckmans P; Klastersky J
Eur J Cancer Clin Oncol; 1989 Jun; 25(6):965-72. PubMed ID: 2787749
[TBL] [Abstract][Full Text] [Related]
30. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
31. In vivo time and dose dependency of interleukin-6 secretion in response to low-dose subcutaneous recombinant interleukin-2.
Meffert M; Hanninen EL; Menzel T; Schomburg A; Duensing S; Dallmann I; Grosse J; Vocke S; Buer J; Deckert M
Cancer Biother; 1994; 9(4):307-16. PubMed ID: 7719378
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy.
Olencki T; Finke J; Tubbs R; Tuason L; Greene T; McLain D; Swanson SJ; Herzog P; Stanley J; Edinger M; Budd GT; Bukowski RM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):69-80. PubMed ID: 8859726
[TBL] [Abstract][Full Text] [Related]
34. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
35. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
36. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
37. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
38. Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Gratama JW; Bruin RJ; Lamers CH; Oosterom R; Braakman E; Stoter G; Bolhuis RL
Clin Exp Immunol; 1993 May; 92(2):185-93. PubMed ID: 8485906
[TBL] [Abstract][Full Text] [Related]
39. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
[TBL] [Abstract][Full Text] [Related]
40. High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma.
Abrams JS; Rayner AA; Wiernik PH; Parkinson DR; Eisenberger M; Aronson FR; Gucalp R; Atkins MB; Hawkins MJ
J Natl Cancer Inst; 1990 Jul; 82(14):1202-6. PubMed ID: 2194036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
